OvaWatchSM is a non-invasive test intended for use in assessing the risk of ovarian cancer for women with adnexal masses that have been considered indeterminate or benign by initial clinical assessment. With its superior negative predictive value, OvaWatch allows physicians to confidently choose the appropriate clinical management path for their patients.
On September 20, 2023, Aspira Women’s Health hosted a Key Opinion Leader Webinar on Assessing Ovarian Cancer Risk with OvaWatch℠. If you missed our live discussion, you don’t have to miss out! Watch now to learn how OvaSuite℠ can help give you confidence in making the right treatment decision for any patient with an adnexal mass, regardless of age or menopausal status.
The OvaWatch blood test combines the results of:
• Seven tumor biomarkers
• Menopausal status
Provides a single risk assessment score delivering a Negative Predictive Value of over 99%1
Giving you confidence in a low probability of malignancy result for both premenopausal and postmenopausal patients
The OvaWatch report includes:
- OvaWatchSM risk score
- Ovarian cancer risk assessment
- CA 125 result
- HE4 result
Example OvaWatch Report
Utilize OvaWatch in your practice to confidently develop your
A single blood draw – which can be performed in a healthcare provider’s offices using our proprietary testing kit or at a number of national and regional laboratories – is all that is needed.
Download Our New Clinical Study Describing Real-World Evidence Supporting The Use Of OvaWatchSM For The Clinical Management Of Adnexal Masses, Entitled:
Planning for surgery?
Learn More About Ova1Plus
Utilize the OvaSuite portfolio of products and confidently move from assessment to action.
A single blood draw – which can be performed at a number of national and regional laboratories or in a healthcare provider's offices using our proprietary testing kit – is all that is needed.
Contact us to learn more, order kits, or to locate one of our phlebotomy partners.
- Analytical Validation of a Deep Neural Network Algorithm for the Detection of Ovarian Cancer. Reilly G, Bullock R, Greenwood J, Ure DR, Stewart E, Davidoff P, DeGrazia J, Fritsche H, Dunton CJ, Bhardwaj N, and Northrop LE. JCO Clinical Cancer Informatics 6:e2100192 2022